GL261

Scopus BioPharma’s Subsidiary — Duet BioTherapeutics — Presents Compelling New Data for a Novel Treatment for Malignant Glioma at 38th Annual Meeting of the Society for Immunotherapy of Cancer

Retrieved on: 
Martedì, Novembre 7, 2023
Neoplasm, Survival, CAR, Combination, Glioma, Therapy, ASO, Regeneron Pharmaceuticals, Head, PD-1, The Co Founder, Merck, CNS, Microglia, Kidney, Bladder cancer, TLR9, OTCQB, CD8, Mouse, Environment, City, Immunotherapy, B cell, Disease, Survival rate, Brain, Society, GL261, Patient, Immunosuppression, Therapure BioPharma Inc, Pharmaceutical industry, Pembrolizumab, Cancer, Duet

NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Scopus BioPharma Inc. (OTCQB: “SCPS”) and its majority-owned subsidiary, Duet BioTherapeutics Inc., presented compelling new data that DUET-102 in combination with PD-1 blockade demonstrates significant anti-tumor activity in models of malignant glioma.

Key Points: 
  • DUET-102 is a double-stranded antisense oligonucleotide (“ASO”) STAT3 inhibitor linked to a TLR9 immune activator being developed for the treatment of glioma.
  • Glioma is a common type of tumor originating in the glial cells of the brain.
  • DUET-102, as a monotherapy, inhibited tumor growth and extended survival of mice in U251, GL261, and QPP8 models of glioma.
  • There is an acute need for new treatment options for glioma, which have seen no significant advances in the past decade.

Beactica Therapeutics to present update on LSD1 programme at the AACR Annual Meeting 2023

Retrieved on: 
Martedì, Aprile 11, 2023
Orange County Convention Center, LSD1, Radiation, Temozolomide, GBM, American Association for Cancer Research, Glioblastoma, GL261, Section 24 of the Constitution of Australia, Standard of care, Cancer, Orphan, Immunology, FDA, Therapy, Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Immunotherapy

STOCKHOLM, April 11, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its LSD1 programme has been selected for a poster presentation at the American Association for Cancer Research's Annual Meeting 2023.

Key Points: 
  • STOCKHOLM, April 11, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its LSD1 programme has been selected for a poster presentation at the American Association for Cancer Research's Annual Meeting 2023.
  • The conference will take place on April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.
  • Dr Konrad Koehler, Head of Discovery, will present a poster entitled Potentiation of Immunotherapy by LSD1 Modulation on Sunday April 16, 2023, at 1:30 PM – 5:00 PM.
  • Organised by the American Association for Cancer Research, the AACR Annual Meeting is the largest and most important cancer drug discovery event in the world.

Beactica Therapeutics to present update on LSD1 programme at the AACR Annual Meeting 2023

Retrieved on: 
Martedì, Aprile 11, 2023
Orange County Convention Center, LSD1, Radiation, Temozolomide, GBM, American Association for Cancer Research, Glioblastoma, GL261, Section 24 of the Constitution of Australia, Standard of care, Cancer, Orphan, Immunology, FDA, Therapy, Health, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Immunotherapy

STOCKHOLM, April 11, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its LSD1 programme has been selected for a poster presentation at the American Association for Cancer Research's Annual Meeting 2023.

Key Points: 
  • STOCKHOLM, April 11, 2023 /PRNewswire/ -- Beactica Therapeutics AB, the Swedish precision oncology company, today announced that its LSD1 programme has been selected for a poster presentation at the American Association for Cancer Research's Annual Meeting 2023.
  • The conference will take place on April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.
  • Dr Konrad Koehler, Head of Discovery, will present a poster entitled Potentiation of Immunotherapy by LSD1 Modulation on Sunday April 16, 2023, at 1:30 PM – 5:00 PM.
  • Organised by the American Association for Cancer Research, the AACR Annual Meeting is the largest and most important cancer drug discovery event in the world.